Physician profile
Michael Anthony Basha
NPI 1598732430
$2,436.38
in general payments reported to CMS, 2019-2025
26 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $144 · 2021: $167 · 2022: $232 · 2023: $456 · 2024: $335 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.40 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $538.52 | 2019-2024 | Airsupra, Breztri, Symbicort |
| Glaxosmithkline, LLC. | $501.16 | 2019-2024 | Trelegy Ellipta, Nucala |
| Amgen INC. | $177.92 | 2019-2025 | Tezspire |
| Genentech USA, INC. | $162.75 | 2019-2023 | Xolair |
| Genzyme Corporation | $155.33 | 2019-2024 | |
| Grifols USA, LLC | $99.33 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.08 | 2019-2020 | |
| Intuitive Surgical, INC. | $90.91 | 2024 | |
| Philips North America LLC | $90.65 | 2019-2025 | Vest Therapy Und |
| Regeneron Healthcare Solutions, INC. | $84.91 | 2019-2024 | Dupixent |
| Inogen, INC. | $50.12 | 2022-2024 | Inogen |
| Csl Behring | $48.52 | 2020 | |
| Pulmonx Corporation | $47.58 | 2020-2021 | |
| Mylan Specialty L.P. | $39.84 | 2019-2022 | |
| Insmed, INC. | $37.82 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $31.79 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.63 | 2019 | |
| Portola Pharmaceuticals, LLC | $28.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.30 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $19.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.61 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.85 | 2020 | |
| Covidien LP | $14.20 | 2019 | |
| Bard Access Systems, INC. | $12.66 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Nabriva Therapeutics, Plc | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Basha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.